Drug intelligence / Profile preview

PG-760564

Development stage: Phase 2
Lead developer: Procter & Gamble
Modality: Small Molecules
Administration: Oral

Overview

PG-760564 is an orally administered small molecule inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), developed as a potential antirheumatic agent. The drug was initially developed by Procter & Gamble and later became part of Warner Chilcott's portfolio following acquisition. Its primary indication was rheumatoid arthritis, where it was evaluated in phase 2 clinical trials for safety, efficacy, and pharmacokinetics in adult patients receiving methotrexate. The mechanism of action involves inhibition of the p38 MAPK pathway, which plays a key role in inflammatory processes relevant to rheumatoid arthritis[1][2][4].

Other names: CHEMBL3545398CHEMBL-3545398CHEMBL 3545398

Targets

MAPK14 (p38 mitogen-activated protein kinase alpha)

Beyond the preview

Go deeper on PG-760564.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PG-760564.

Explore the full profile